BD announced positive 9-month results from the AGILITY trial for its Revello™ Vascular Covered Stent treating iliac artery disease, showing 97.2% vessel patency and 98.3% freedom from reintervention. The study involved 120 patients across multiple countries and demonstrated strong safety, effectiveness, and improved patient mobility. These results support the stent as a durable treatment option for complex peripheral artery disease, with ongoing follow-up through 36 months to further assess long-term outcomes.
BD's positive AGILITY trial results for its Revello™ Vascular Covered Stent provide context for health innovation. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 19:12 WIB: out of 100 priced US health stocks, 44 rose and 50 fell. Notable movers include NUWE at USD 0.68 with a 2.41% decline, MESO at USD 13.93 up 2.35%, and DHR at USD 220.38 up 2.24%.
XRP's price fell to around $1.45 following a $3.14 million net inflow into U.S. spot XRP ETFs on October 6, with Bitwise's inflows offsetting withdrawals from other funds. Despite the inflows, XRP dropped sharply during a crypto market selloff, losin...
Lakewood-Amedex Biotherapeutics announced that their Bisphosphocin® compound Nu-8 achieved up to 97% inhibition of E. coli growth in rodents with urinary tract infections. The Bisphosphocin® class also demonstrated broad activity against resistant ba...
Mantle (MNT) fell sharply by 11.4%, breaking its $0.6 support level and hitting a low of $0.54 before recovering slightly to $0.58. The decline was driven by intense selling pressure in the derivatives market, with open interest dropping 14% and deri...
Verizon and AT&T both offer attractive dividend yields, but Verizon stands out as the more reliable choice for long-term investors. Verizon's dividend yield is higher at 6.2%, supported by strong free cash flow growth, manageable debt levels, and a c...
Credo Technology, a company providing critical connectivity components for AI infrastructure, is experiencing rapid revenue growth of over 114% year-over-year, outperforming expectations with $479 million in quarterly revenue. Despite a recent stock ...
